Could A New Potential Treatment Lead To Safer IVF Affecting 2% Of All UK Born Babies

(Newswire.net — July 28, 2014) Alicante, Alicante — 

 

This latest IVF treatment report is based on brand-new research which supports evidence that a natural hormone known as kisspeptin-54 can be used to stimulate egg maturation in women that would require in vitro fertilization (IVF) treatment to get pregnant.

Ovarian hyper-stimulation is one of the dangers in IVF treatment, and analysts at Imperial College London have released a info packed video describing their kisspeptin research and its ramifications. The current IVF treatment on trial is said to be more secure than conventional IVF, and has already resulted in 12 healthy newly born babies from 53 females having gone through just one single IVF treatment.

 

So what are the primary implications of being able to use kisspeptin-54? Researchers are saying that such treatment ought to result in a more secure version of in vitro fertilization by decreasing the need to utilize human chorionic gonadotropin (hCG), where a slight risk of triggering ovarian hyper-stimulation syndrome (OHSS) is already known, which can be potentially dangerous.

The research so far performed looked mainly at using different dosages of kisspeptin-54, though not actually compared to present IVF treatments, and researchers are saying that the total effectiveness and safety of the new IVF treatment still needs to be studied against existing IVF treatments, in order to see which actually provides for better total success rates.

The study itself was performed by researchers from Imperial College London and Hammersmith Health center, and was funded by the Medical Research Council, National Trust and National Institute for Health Research. The research was published in The Journal of Clinical Investigation, a peer-reviewed clinical journal and states that this was a randomized professional trial (RCT) examining whether a brand-new hormone could be utilized in the early stages of IVF to potentially enhance current safety limits.

The analysts randomly selected 53 women who had opted for IVF to various doses of kisspeptin-54 treatment. They wanted to see whether it might partially replace the hormone generally made use of to stimulate the maturation of eggs during IVF. The analysts main objective was to know whether a single treatment of kisspeptin produced egg maturation. They examined this by looking at the number of mature eggs, and the percentage of all eggs gathered that were mature. Secondary testing included the later stages of IVF, such as fertilization rates, effective implantation rates, maternity rates and healthy births.

Researchers are quoted as saying “the study demonstrates that a single injection of kisspeptin-54 can induce egg maturation in females with sub-fertility undergoing IVF therapy. Subsequent fertilization of eggs developed following kisspeptin-54 treatment and transfer of resulting embryos can result in a successful pregnancy.”.

This research provided “proof of principle” that the natural hormone kisspeptin-54 can be utilized to promote egg maturation in females needing IVF. The customized IVF; which is hoped to be more secure than standard IVF, resulted in 12 healthy children being born from 10 women from a total of 53 women undergoing a single IVF treatment, concluding with a 19 % success rate.

Some of the highest European IVF success rates are actually in Spain, with IVF-Spain leading the way. All of the different IVF treatments can be seen as a comparable against the Spanish national averages here: http://ivf-spain.com/meet-ivf-spain/results/

 

 

 

 

——-